Camrelizumab
- Generic Name
- Camrelizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 62
- Registration Number
- NCT04167774
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China
🇨🇳The first affiliated hospital of guangzhou medical university, Guangzhou, Guangdong, China
Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Eye & ENT Hospital of Fudan University
- Target Recruit Count
- 51
- Registration Number
- NCT04156698
- Locations
- 🇨🇳
Eye & ENT Hospital, Fudan University, Shanghai, Shanghai, China
A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04152889
- Locations
- 🇨🇳
Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Shanghai Proton and Heavy Ion Center
- Target Recruit Count
- 146
- Registration Number
- NCT04143984
- Locations
- 🇨🇳
Shanghai Proton and Heavy Ion Center, Shanghai, Shanghai, China
Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC
- Conditions
- Interventions
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- Sichuan Cancer Hospital and Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT04133337
- Locations
- 🇨🇳
Sichuan Cancer Hospital, Chengdu, Sichuan, China
A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC
- Conditions
- Interventions
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2019-09-27
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 38
- Registration Number
- NCT04108013
Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT04102982
- Locations
- 🇨🇳
Binzhou Medical University Hospital, Binzhou, Shandong, China
🇨🇳Liaocheng Cancer Hospital, Liaocheng, Shandong, China
🇨🇳Jinan Military General Hospital, Jinan, Shandong, China
Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Zhongshan Hospital Xiamen University
- Target Recruit Count
- 62
- Registration Number
- NCT04067986
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Xiamen University, Xiamen, Fujian, China
Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Beijing Sanbo Brain Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT04070040
- Locations
- 🇨🇳
Sanbo Brain Hospital Capital Medical University, Beijing, China
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04067037
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.